About - Aria Pharmaceuticals

about us

ABOUT US

An aria is an elaborate, sophisticated section in an opera reserved for the top performer. Just as an aria boldly advances the plot, we are dedicated to advancing bold breakthroughs in medicine. At Aria Pharmaceuticals, we believe in the work we do for patients in need. Our name exhibits the artistry and complexity that defines how we approach medicine from idea to FDA approval in a way that is scientifically sound.

management

Andrew A. Radin
CEO & Co-founder

Andrew A. Radin is the co-founder and Chief Executive Officer of Aria Pharmaceuticals. Andrew created the company’s first drug development algorithms as part of his studies in biomedical informatics at Stanford University in 2014. Since co-founding Aria, Andrew was named an Emerging Pharma Leader by Pharma Executive magazine, was invited to give a TEDMED talk, and was named a Top 100 AI Leader by Deep Knowledge Analytics. In addition to his duties as CEO at Aria, Andrew serves as an advisor to Stanford University’s SPARK drug development and Stanford University’s StartX startup accelerator programs. Prior to co-founding Aria, Andrew served as Chief Technology Officer at several successful internet startups. His prior projects have reached tens of millions of people in telephony systems, advertising networks, video games, and geographical mapping systems. Andrew studied Biomedical Informatics at Stanford University’s SCPD graduate program and holds a Master of Science and Bachelor of Science degrees in Computer Science from Rochester Institute of Technology.

Mark Eller, PhD
Senior Vice President of R&D

Mark Eller brings 30 years of pharmaceutical R&D experience, including VP/SVP roles leading teams from discovery through approval. Mark’s previous experience encompasses both large (Quintiles, HMR/Sanofi predecessors) and small-to-midsize pharma companies (Jazz Pharmaceuticals) spanning a broad range of therapeutic areas. Mark has four FDA-approved drugs to his credit and is co-inventor on 30 patents. In addition he has led health authority presentations and negotiations, including six FDA advisory committee meetings. He has co-authored numerous scientific publications and served as an Adjunct Professor of Pharmaceutics at the University of Cincinnati. Mark received his Pharmacy degree and Ph.D. in Pharmaceutics from the University of Iowa.

Anjali Pandey, PhD
SENIOR VICE PRESIDENT OF NONCLINICAL R&D AND CHEMISTRY

Anjali Pandey is an executive leader with 25+ years of experience in CSO/SVP roles through all stages of discovery through launch. Anjali previously served as SVP of Medicinal Chemistry & Chemical Development at Portola Pharmaceuticals, where she managed discovery and CMC for Bevyxxa™ and Cerdulatinib. Most recently, Anjali held CSO/EVP positions at BridgeBio Pharma subsidiaries TheRas and Ferro Therapeutics. Anjali has published over 45 scientific publications and is inventor on 60 issued U.S. patents. She holds an MS from the Indian Institute of Technology, a PhD from Southern Illinois University, and completed her postdoctoral fellowship at SRI International.

Aaron C. Daugherty PhD
VICE PRESIDENT OF DISCOVERY

One of Aria Pharmaceuticals’ first employees, Aaron C. Daugherty has helped build Aria’s drug discovery platform and leads the Discovery Science team’s efforts to discover potential treatments across a wide range of diseases. Aaron earned his PhD in Genetics from Stanford University. Prior to his time at Stanford, Aaron was a Fulbright Scholar and received his Bachelor of Science in Biology from the University of Richmond.